Actelion’s clinical development activities include the characterization of macitentan in specific PAH patient populations as well as expanding its use beyond PAH.
Evaluates the effect on the physical activity of patients with PAH in their daily life, by using a wearable wrist device
|Macitentan||Portopulmonary hypertension (PoPH)||PORTICO||Data analysis ongoing|
|Macitentan||Evaluates the effect on right ventricular remodeling and hemodynamic properties in patients with symptomatic PAH||REPAIR||Ongoing|
|Phase IIIb||Selexipag||Compares the efficacy and safety of an initial triple oral treatment regimen of macitentan together with tadalafil and selexipag versus an initial dual oral treatment regimen in newly diagnosed, treatment-naïve patients with PAH||TRITON||Ongoing|
|Macitentan||Long-term safety data in PAH patients||UMBRELLA||Ongoing|
|Phase III||Macitentan||Pediatric PAH||TOMORROW||Ongoing|
|Phase II||Macitentan||Chronic thromboembolic pulmonary hypertension||MERIT||Regulatory process|
|Phase IIb||Macitentan||Evaluates the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease||SERENADE||Ongoing|
"I'm part of a team which develops new therapies for patients who have few options."